Form 8-K - Current report:
SEC Accession No. 0001193125-24-228441
Filing Date
2024-09-30
Accepted
2024-09-30 08:00:32
Documents
13
Period of Report
2024-09-27
Items
Item 8.01: Other Events

Document Format Files

Seq Description Document Type Size
1 8-K d718563d8k.htm   iXBRL 8-K 42593
  Complete submission text file 0001193125-24-228441.txt   172596

Data Files

Seq Description Document Type Size
2 XBRL TAXONOMY EXTENSION SCHEMA pstx-20240927.xsd EX-101.SCH 2838
3 XBRL TAXONOMY EXTENSION LABEL LINKBASE pstx-20240927_lab.xml EX-101.LAB 18737
4 XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE pstx-20240927_pre.xml EX-101.PRE 11699
15 EXTRACTED XBRL INSTANCE DOCUMENT d718563d8k_htm.xml XML 3777
Mailing Address 9390 TOWNE CENTRE DRIVE SUITE 200 SAN DIEGO CA 92121
Business Address 9390 TOWNE CENTRE DRIVE SUITE 200 SAN DIEGO CA 92121 858-779-3100
Poseida Therapeutics, Inc. (Filer) CIK: 0001661460 (see all company filings)

EIN.: 472846548 | State of Incorp.: DE | Fiscal Year End: 1231
Type: 8-K | Act: 34 | File No.: 001-39376 | Film No.: 241336712
SIC: 2836 Biological Products, (No Diagnostic Substances)
(CF Office: 03 Life Sciences)